At the forefront of innovation 

The aim of this project is to fight against Multi-Drug Resistant (MDR) Mycobacterium tuberculosis (M. tuberculosis) (TB) and Methicillin Resistant Staphylococcus aureus (MRSA), leading to serious diseases which usually require intensive care treatment with a long hospitalization. The project proposes nanotechnology solutions to this problem by the design, the preparation and the optimization of several nanoformulations of current antibiotics and novel antibacterial drugs.

The company´s main contribution is related to physicochemical characterization of nanodelivery sistems, biological and immunological characterization, both in vitro and in vivo, and biodistribution in order to test the safety of the nanosystems developed and to validate cell targeting.